



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Liggett et al.

Attorney Docket: 13105

Serial No.: 09/692,077

Examiner: Unassigned

Dated Filed: October 19, 2000

Group Art Unit: 1614

For: Alpha-2B-Adrenergic Receptor Polymorphisms

RECEIVED

FEB 15 2002

TECH CENTER 1600/2900

Kalow & Springut, LLP  
488 Madison Avenue, 19th Floor  
New York, NY 10022

COPY OF PAPERS  
ORIGINALLY FILED

Dated: January 3, 2002

Assistant Commissioner for Patents  
Washington, DC 20231

TRANSMITTAL OF SEQUENCE LISTING

Sir:

The computer readable copy of the sequence listing and the attached paper copy are identical. Pursuant to 37 CFR §§ 1.821 - 1.825, no new matter has been added.

Respectfully submitted,





William D. Schmidt  
Registration No. 39,492

Telephone (212)813 1600

Certificate of Mailing Under 37 C.F.R. 1.8

I hereby declare that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C.

Date: 1/3/02 Name: 



COPY OF PAPERS  
ORIGINALLY FILED

PATENT

FP 1613  
H9/B  
CD  
FEB 08 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Liggett et al.

Examiner: Unassigned

Serial No.: 09/692,077

Group Art Unit: 1614

Filed: October 19, 2000

Docket: 13105

For: Alpha-2B-Adrenergic Receptor Polymorphisms

Dated: January 3, 2002

Assistant Commissioner for Patents  
Washington, DC 20231

RECEIVED

FEB 15 2002

TECH CENTER 1600/2900

**REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO  
ACID SEQUENCE DISCLOSURES**

SIR:

In reply to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures issued in connection with the above-identified patent application on December 3, 2001, enclosed herewith is a substitute copy of the "Sequence Listing" in computer readable form and paper copy pursuant to 37 CFR §1.821 - 1.825. A copy the Notice is also enclosed.

The deadline for reply to the Notice was set for January 3, 2001. Accordingly, this reply is timely filed.

**Certificate of Mailing Under 37 C.F.R. 1.8**


I hereby declare that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C.

Date: 1/3/02 Name: J. Colwell

Applicant: Liggett et al.  
Serial No.: 09/692,077  
Docket No.: 13105

No fee is believed to be due. If a fee is deemed to be due or any overpayment has been made, please charge our Deposit Account No. 11-0171 or credit our Deposit account for such sum. A duplicate copy of this sheet is enclosed for that purpose.

Respectfully submitted,



William D. Schmidt  
Registration No.: 39,492  
Attorney for Applicants

OIP ENCL  
FEB 08 2001  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 111 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: The new paper Sequence Listing filed March 16, 2001 was not accompanied by a computer readable form.

### Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

COPY OF PAPERS  
ORIGINALLY FILED